Skip to main content
. 2023 Jun 20;26(6):407–415. [Article in Chinese] doi: 10.3779/j.issn.1009-3419.2023.102.18

表5.

PD-L1 1%-49%晚期或转移性NSCLC的免疫治疗方案

Pathological
subtype 		First-line therapy Continuation maintenance
Preferred Other recommended
Adenocarcinoma, large cell, NSCLC not otherwise specified Carboplatin or Cisplatin+
Pemetrexed+
Pembrolizumab (category 1)		 Carboplatin+Paclitaxel+Bevacizumab+Atezolizumab (category 1);
Carboplatin+albumin-bound Paclitaxel+Atezolizumab;
Nivolumab+Ipilimumab+Pemetrexed+Carboplatin or Cisplatin (category 1);
Nivolumab+Ipilimumab (category 1);
Cemiplimab-rwlc+Paclitaxel+Carboplatin or Cisplatin (category 1);
Cemiplimab-rwlc+Pemetrexed+Carboplatin or Cisplatin (category 1);
Tremelimumab-actl+Durvalumab+ Carboplatin+albumin-bound Paclitaxel (category 1);
Tremelimumab-actl+Durvalumab+Carboplatin or Cisplatin+Pemetrexed (category 1)		 Pembrolizumab (category 2B); Pembrolizumab+Pemetrexed (category 1);
Atezolizumab+Bevacizumab (category 1);
Atezolizumab;
Nivolumab+Ipilimumab (category 1);
Cemiplimab-rwlc±Pemetrexed (category 1);
Durvalumab±Pemetrexed
Squamous cell carcinoma Carboplatin+Paclitaxel or albumin-bound
Paclitaxel+
Pembrolizumab (category 1)		 Nivolumab+Ipilimuab+Paclitaxel+Carboplatin (category 1);
Nivolumab+Ipilimumab (category 1);
Cemiplimab-rwlc+Paclitaxel+Carboplatin or Cisplatin (category 1);
Tremelimumab-actl+Durvalumab+
Carboplatin+albumin-bound Paclitaxel;
Tremelimumab-actl+Durvalumab+Carboplatin or Cisplatin+Gemcitabine		 Pembrolizumab;
Nivolumab+Ipilimumab (category 1);
Cemiplimab-rwlc (category 1); Durvalumab